19 July 2006 in European Journal of Haematology
14 October 2008 in British Journal of Haematology
Summary: A combination of clarithromycin, low dose of thalidomide and low dose dexamethasone was used in a phase II study to treat patients with relapsed and refractory myeloma. Thirty patients received clarithromycin 250 mg twice daily and thalidomide 50 mg at night on an ongoing basis with 4‐d pulses of 10 mg dexamethasone given monthly. Eight patients had permitted escalation of thalidomide dosage up to 200 mg daily. The combination was well tolerated and could be given to elderly, infirm and severely cytopenic patients. Response rates were high, with 89% achieving at least 50% reduction in paraprotein and a 96% overall response rate. Although clarithromycin has only minimal anti‐myeloma properties when used as a single agent, its combination with thalidomide and dexamethasone appears very effective, allowing these to be used in lower and more tolerable doses with good clinical effects.
1 January 2003 in Leukemia & Lymphoma
15 July 2004 in Journal of Clinical Oncology
6550 Background: Bortezomib (Velcade, formerly PS341) (P) shows encouraging clinical results in patients (pts) with relapsed MM with dexamethasone showing additive benefit. In vitro, P demonstrates potent synergy with cytotoxics including anthracyclines. Therefore, a Phase I/II study of PAD combination was undertaken in patients with previously untreated MM. The study objectives were: feasibility of peripheral blood stem cell (PBSC) collection and support for high dose melphalan (HDM); safety, toxicity and response rate. Methods: Pts with previously untreated MM were eligible. Pts received 4x21 day cycles of PAD. All pts received P 1.3mg/m2 on days 1,4,8,11 and oral D 40mg days 1–4, 8–11, 15–18 Cycle 1 (day 1–4 only cycles 2–4). Level 1 pts received no doxorubicin [Adriamycin (A)], level 2 pts received 4.5mg/m2 d1–4, level 3 received 9mg/m2 d1–4. Following PBSC harvesting, HDM with PBSC rescue was given. In vitro testing included gene expression analysis on purified plasma cells to identify gene expression profiles associated with response and known prognostic factors. Results: Fifteen pts are enrolled (1F; median age 52 [37–64] yrs) and all have completed at least 1 cycle (Level 1 –3 pts; level 2 –4 pts; level 3 –8 pts). All pts have achieved at least a partial response with 2 achieving a complete response by immunofixation (1 at level 1; 1 at level 3). In 8/8 pts PBSC collection was successful (median 3.13 x106 CD34+ cells/kg (1.92–7.4). 6 pts have completed HDM with PBSCs. Median time to neutrophil (>0.5) and platelet (>20) engraftment was 18 days (13–23) and 12.5 days (10–33). Most adverse events were NCI-CTC Grade 1–2. Of 6 serious adverse events only 2 were considered to be possibly study drug related. There were no deaths on study. Conclusion: PAD is well tolerated, highly effective and does not prejudice PBSC collection or subsequent engraftment. PAD warrants further evaluation in prospective clinical trials.